CCRCC
MCID: CLR030
MIFTS: 53

Clear Cell Renal Cell Carcinoma (CCRCC)

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 12 52 58 15
Clear-Cell Metastatic Renal Cell Carcinoma 12 52 71
Clear Cell Carcinoma of Kidney 12 29 6
Conventional Renal Cell Carcinoma 12 71
Renal Clear Cell Carcinoma 12 54
Clear Cell Renal Cell Adenocarcinoma 58
Conventional Renal Cell Carcinoma 12
Clear Cell Kidney Carcinoma 12
Cystic-Multilocular Variant 52
Clear Cell Renal Carcinoma 58
Clear Cell Rcc 52
Ccrcc 58

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 43 D002292
NCIt 49 C4033
SNOMED-CT 67 254915003
ICD10 via Orphanet 33 C64
UMLS via Orphanet 72 C0279702
Orphanet 58 ORPHA319276
UMLS 71 C0279702 C2931852

Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 52 Clear cell renal cell carcinoma is a cancer of the kidney . The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope. Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass ). Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome ) may contribute to the development of this type of cancer. Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy , chemotherapy , biological therapy , or targeted therapy .

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and chromophobe renal cell carcinoma, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is VHL (Von Hippel-Lindau Tumor Suppressor). The drugs Sorafenib and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells.

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 34.3 VHL TUG1 SPRY4-IT1 PVT1 PBRM1 PANDAR
2 chromophobe renal cell carcinoma 33.7 VHL PBRM1 OGG1 HNF1A FLCN
3 kidney cancer 32.9 VHL PVT1 PBRM1 MEG3 MALAT1 FLCN
4 renal cell carcinoma, papillary, 1 32.0 VHL PBRM1 FLCN
5 collecting duct carcinoma 31.7 VHL PBRM1 FLCN
6 clear cell papillary renal cell carcinoma 31.5 VHL PBRM1 HNF1A
7 bladder cancer 31.0 TUG1 SPRY4-IT1 PVT1 PANDAR OGG1 MEG3
8 intrahepatic cholangiocarcinoma 30.9 TUG1 PBRM1 CCAT2
9 cholangiocarcinoma 30.9 TUG1 SPRY4-IT1 PANDAR OGG1 MALAT1 CCAT2
10 lung squamous cell carcinoma 30.7 TUG1 PVT1 OGG1 MEG3 CCAT2
11 myeloma, multiple 30.7 TUG1 PVT1 MEG3 MALAT1
12 osteogenic sarcoma 30.7 TUG1 PVT1 PANDAR MEG3 MALAT1 LUCAT1
13 esophageal cancer 30.6 PVT1 OGG1 MEG3 MALAT1 LUCAT1 CYTOR
14 lung cancer susceptibility 3 30.6 TUG1 OGG1 MEG3 MALAT1 DGCR5 CYTOR
15 pituitary adenoma 30.6 MEG3 MALAT1 CCAT2
16 bladder urothelial carcinoma 30.5 TUG1 PVT1 MEG3 MALAT1
17 oral squamous cell carcinoma 30.5 TUG1 MEG3 MALAT1 CCAT2
18 gallbladder cancer 30.5 TUG1 MEG3 MALAT1 CYTOR
19 gastric cancer 30.5 TUG1 SPRY4-IT1 PVT1 PANDAR OGG1 MEG3
20 lung cancer 30.2 VHL TUG1 SPRY4-IT1 PVT1 PANDAR OGG1
21 hepatocellular carcinoma 30.2 TUG1 SPRY4-IT1 PVT1 PANDAR MEG3 MALAT1
22 thyroid cancer, nonmedullary, 1 30.2 MEG3 MALAT1
23 multilocular clear cell renal cell carcinoma 12.7
24 hereditary conventional renal cell carcinoma 12.7
25 multilocular cystic renal neoplasm of low malignant potential 11.9
26 von hippel-lindau syndrome 11.9
27 bap1 tumor predisposition syndrome 11.7
28 renal cell carcinoma, xp11-associated 11.3
29 chromophil renal cell carcinoma 10.7
30 oncocytoma 10.7
31 angiomyolipoma 10.6
32 glioma 10.6 SPRY4-IT1 PVT1 MEG3 MALAT1 LUCAT1 CYTOR
33 vulva squamous cell carcinoma 10.6 MEG3 MALAT1
34 hypoxia 10.5
35 malignant glioma 10.5 TUG1 SPRY4-IT1 PVT1 MEG3 MALAT1 CYTOR
36 tongue squamous cell carcinoma 10.5 MEG3 MALAT1 CYTOR
37 small cell cancer of the lung 10.5 TUG1 MALAT1 CCAT2
38 esophagus squamous cell carcinoma 10.4 TUG1 MEG3
39 hemangioblastoma 10.4
40 renal cell carcinoma 4 10.4
41 cervical cancer 10.4 TUG1 SPRY4-IT1 PVT1 PANDAR MEG3 MALAT1
42 severe combined immunodeficiency 10.4
43 renal oncocytoma 10.4
44 spindle cell carcinoma 10.4
45 microvascular complications of diabetes 3 10.4 PVT1 MALAT1
46 glioma susceptibility 1 10.3 TUG1 MEG3 MALAT1 DGCR5 CYTOR
47 hypothyroidism 10.3
48 adenoma 10.3
49 exanthem 10.3
50 neutropenia 10.3

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2
Ipilimumab Approved Phase 3 477202-00-9
3
nivolumab Approved Phase 3 946414-94-4
4
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
5
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
6
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
7 interferons Phase 3
8 Interferon-alpha Phase 3
9 Interferon alpha-2 Phase 3
10 Antibodies, Monoclonal Phase 3
11 Mitogens Phase 3
12 Endothelial Growth Factors Phase 3
13 Immunoglobulins, Intravenous Phase 3
14 Immunoglobulin G Phase 3
15
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 46507594 772
16
Tinzaparin Approved Phase 1, Phase 2 9041-08-1, 9005-49-6 25244225
17
Dalteparin Approved Phase 1, Phase 2 9005-49-6
18
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
19
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
20
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
21
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
22
Zoledronic Acid Approved Phase 1, Phase 2 118072-93-8 68740
23
Promethazine Approved, Investigational Phase 2 60-87-7 4927
24
Histamine Approved, Investigational Phase 2 51-45-6 774
25
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
26
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
27
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
28
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
29
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
32
Acetaminophen Approved Phase 2 103-90-2 1983
33
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
34
Benzyl alcohol Approved Phase 2 100-51-6 244
35
Ethanol Approved Phase 2 64-17-5 702
36
Denosumab Approved Phase 2 615258-40-7
37
Selenium Approved, Investigational, Vet_approved Phase 1, Phase 2 7782-49-2
38
Clobetasol Approved, Experimental, Investigational Phase 2 25122-41-2, 25122-46-7 32798 5311051
39
Olaparib Approved Phase 2 763113-22-0 23725625
40
Adenosine Approved, Investigational Phase 2 58-61-7 60961
41
Talazoparib Approved, Investigational Phase 1, Phase 2 1207456-01-6 135565082
42
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
46
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
47
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
48
Racepinephrine Approved Phase 2 329-65-7 838
49
Radium Ra 223 dichloride Approved, Investigational Phase 1, Phase 2 444811-40-9
50
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
2 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
3 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
4 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
5 Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making. Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
6 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
7 A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) Completed NCT00087022 Phase 3
8 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
9 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
10 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
11 An International, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate Whether TroVax, Added to First-line Standard of Care Therapy, Prolongs the Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma. Completed NCT00397345 Phase 3
12 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma Completed NCT00326898 Phase 3 Sorafenib Tosylate;Sunitinib Malate
13 A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses Recruiting NCT03849118 Phase 3
14 PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Recruiting NCT03793166 Phase 3 Cabozantinib
15 A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Active, not recruiting NCT01668784 Phase 3 Everolimus
16 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Active, not recruiting NCT01120249 Phase 3 everolimus
17 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
18 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Terminated NCT02535351 Phase 3 sunitinib or pazopanib
19 Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC Terminated NCT01599754 Phase 3 Axitinib;Placebo
20 Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors Terminated NCT01198158 Phase 3 Everolimus
21 An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma Withdrawn NCT03693573 Phase 3 Atezolizumab;Bevacizumab
22 A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
23 "PADRES" (Prior Axitinib as a Determinant of Outcome of REnal Surgery) Unknown status NCT03438708 Phase 2 Axitinib Oral Tablet [Inlyta]
24 A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus Unknown status NCT01798446 Phase 2 Axitinib
25 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Unknown status NCT02771626 Phase 1, Phase 2 CB-839;Nivolumab
26 Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma Unknown status NCT01219751 Phase 2 Sunitinib
27 A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer Unknown status NCT02960906 Phase 2 Nivolumab;Ipilimumab;Pazopanib;Sunitinib
28 Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study Unknown status NCT01069770 Phase 2 Sunitinib
29 Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
30 A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
31 A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study Unknown status NCT00301990 Phase 2
32 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Unknown status NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
33 SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies Unknown status NCT00535379 Phase 2 Sunitinib
34 Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study Unknown status NCT01791387 Phase 2 Dovitinib
35 A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00278174 Phase 2
36 A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy Completed NCT02724020 Phase 2 Everolimus;MLN0128;MLN1117
37 Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00408902 Phase 2 tandutinib
38 G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
39 Phase II Study Of Lutetium-177 Labeled Chimeric Monoclonal Antibody Girentuximab (177Lu-DOTA-girentuximab) in Patients With Advanced Renal Cell Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
40 Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma Completed NCT00401128 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
41 Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma Completed NCT00853021 Phase 2
42 A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma Completed NCT00830895 Phase 2 RAD001
43 Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Completed NCT00465179 Phase 2 Sunitinib Malate
44 Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma Completed NCT00979966 Phase 2 Temsirolimus;Sunitinib
45 A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
46 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2 pazopanib
47 An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
48 A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma Completed NCT02923531 Phase 1, Phase 2 X4P-001;Nivolumab
49 Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer Completed NCT00142415 Phase 1, Phase 2 111-In-DOTA-cG250;177-Lu-DOTA-cG250
50 Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Completed NCT01182142 Phase 2 Capecitabine

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Genetic tests related to Clear Cell Renal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 29

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

40
Kidney, Endothelial, T Cells, Lung, Brain, Neutrophil, Thyroid

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 4015)
# Title Authors PMID Year
1
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. 61 54
20431476 2010
2
Loss of expression of TIMP3 in clear cell renal cell carcinoma. 61 54
20194016 2010
3
The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. 54 61
19683801 2010
4
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. 54 61
19963243 2010
5
The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. 54 61
20022054 2010
6
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 61 54
20054297 2010
7
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. 61 54
19695674 2009
8
Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. 61 54
19731255 2009
9
Microarray analysis of microRNA expression in renal clear cell carcinoma. 46
19443172 2009
10
[Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]. 54 61
20021866 2009
11
Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. 61 54
19219613 2009
12
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. 54 61
19671223 2009
13
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. 54 61
19539328 2009
14
[Methylation of promoter region of RASSF1A gene and frequencies of allelic imbalances in chromosome 3 critical regions are correlated with progression of clear cell renal cell carcinoma]. 54 61
19548529 2009
15
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. 54 61
19296514 2009
16
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. 61 54
19402074 2009
17
Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. 61 54
19302703 2009
18
Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. 54 61
19073886 2009
19
Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. 54 61
19759417 2009
20
Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. 54 61
18660794 2009
21
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. 61 54
18695901 2008
22
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. 54 61
18635227 2008
23
Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. 61 54
18538369 2008
24
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. 54 61
18669472 2008
25
Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. 54 61
18604734 2008
26
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. 61 54
18464292 2008
27
Expression of prostate-specific membrane antigen in renal cortical tumors. 54 61
18344976 2008
28
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. 61 54
18565906 2008
29
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. 61 54
18300814 2008
30
Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. 54 61
18076934 2008
31
Expression of claudin-7 in benign kidney and kidney tumors. 61 54
18784823 2008
32
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. 61 54
17997430 2008
33
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. 61 54
18043042 2007
34
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. 54 61
18094421 2007
35
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. 54 61
17947723 2007
36
Characterization of a 3;6 translocation associated with renal cell carcinoma. 54 61
17205537 2007
37
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. 54 61
17382701 2007
38
Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. 54 61
17449941 2007
39
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. 54 61
17188329 2007
40
Activation of the mTOR signaling pathway in renal clear cell carcinoma. 61 54
17162089 2007
41
[Expression of Ksp-cadherin in renal epithelial neoplasm and its clinicopathologic significance]. 54 61
17374232 2007
42
Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. 54 61
17270362 2007
43
The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. 61 54
16983094 2006
44
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. 61 54
16736510 2006
45
[Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof]. 54 61
16854277 2006
46
Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors. 54 61
16600797 2006
47
[Expression of cytokeratin 5 and calretinin in clear-cell renal cell carcinoma]. 54 61
16838608 2006
48
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. 61 54
16107702 2005
49
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. 54 61
15893810 2005
50
Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. 61 54
15578072 2005

Variations for Clear Cell Renal Cell Carcinoma

ClinVar genetic disease variations for Clear Cell Renal Cell Carcinoma:

6 (show all 22) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HNF1A NM_000545.6(HNF1A):c.814C>T (p.Arg272Cys)SNV Pathogenic 447503 rs1555212014 12:121432067-121432067 12:120994264-120994264
2 VHL NM_000551.3(VHL):c.499C>T (p.Arg167Trp)SNV Pathogenic 2218 rs5030820 3:10191506-10191506 3:10149822-10149822
3 OGG1 NM_016828.2(OGG1):c.137G>A (p.Arg46Gln)SNV Pathogenic 7602 rs104893751 3:9792107-9792107 3:9750423-9750423
4 HNF1A NM_000545.6(HNF1A):c.872dup (p.Gly292fs)duplication Pathogenic 14927 rs587776825 12:121432117-121432118 12:120994314-120994315
5 HNF1A NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu)SNV Pathogenic 14928 rs137853236 12:121435307-121435307 12:120997504-120997504
6 PBRM1 NM_018313.5(PBRM1):c.3923_3930del (p.Asp1308fs)deletion Pathogenic 218955 rs864321679 3:52597380-52597387 3:52563364-52563371
7 FLCN NM_144997.7(FLCN):c.1429C>T (p.Arg477Ter)SNV Pathogenic 253251 rs879255678 17:17118502-17118502 17:17215188-17215188
8 FLCN NM_144997.7(FLCN):c.779+1G>TSNV Pathogenic/Likely pathogenic 231274 rs758175953 17:17125814-17125814 17:17222500-17222500
9 VHL NM_000551.4(VHL):c.319C>G (p.Arg107Gly)SNV Pathogenic/Likely pathogenic 43599 rs397516440 3:10183850-10183850 3:10142166-10142166
10 FLCN NM_144997.7(FLCN):c.134C>G (p.Ala45Gly)SNV Conflicting interpretations of pathogenicity 134423 rs556510460 17:17131318-17131318 17:17228004-17228004
11 HNF1A NM_000545.6(HNF1A):c.92G>A (p.Gly31Asp)SNV Conflicting interpretations of pathogenicity 14948 rs137853247 12:121416663-121416663 12:120978860-120978860
12 VHL NM_000551.3(VHL):c.614G>A (p.Arg205His)SNV Conflicting interpretations of pathogenicity 421823 rs777130107 3:10191621-10191621 3:10149937-10149937
13 HNF1A NM_000545.6(HNF1A):c.1135C>G (p.Pro379Ala)SNV Conflicting interpretations of pathogenicity 431970 rs754729248 12:121434371-121434371 12:120996568-120996568
14 HNF1A NM_000545.6(HNF1A):c.1501+6C>TSNV Conflicting interpretations of pathogenicity 435420 rs374306837 12:121435474-121435474 12:120997671-120997671
15 FLCN NM_144997.7(FLCN):c.1309G>C (p.Val437Leu)SNV Uncertain significance 529982 rs772207015 17:17118622-17118622 17:17215308-17215308
16 VHL NM_000551.3(VHL):c.-73C>TSNV Uncertain significance 560736 rs1034934219 3:10183459-10183459 3:10141775-10141775
17 VHL NM_000551.3(VHL):c.205C>G (p.Arg69Gly)SNV Uncertain significance 573437 rs1428175816 3:10183736-10183736 3:10142052-10142052
18 VHL NM_000551.3(VHL):c.31G>C (p.Ala11Pro)SNV Uncertain significance 456583 rs1236604706 3:10183562-10183562 3:10141878-10141878
19 FLCN NM_144997.7(FLCN):c.451G>A (p.Val151Met)SNV Uncertain significance 460616 rs147164515 17:17127403-17127403 17:17224089-17224089
20 FLCN NM_144997.7(FLCN):c.1430G>A (p.Arg477Gln)SNV Uncertain significance 322061 rs748878853 17:17118501-17118501 17:17215187-17215187
21 VHL NM_000551.4(VHL):c.439A>G (p.Ile147Val)SNV Uncertain significance 371833 rs1057517560 3:10188296-10188296 3:10146612-10146612
22 OGG1 NM_003656.5(CAMK1):c.84-13C>TSNV Likely benign 522323 rs41276495 3:9807587-9807587 3:9765903-9765903

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 6488)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88579140 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 9
2 COSM88566796 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 9
3 COSM100952565 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 9
4 COSM94790253 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 9
5 COSM137390699 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 9
6 COSM149268221 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 9
7 COSM149266502 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 9
8 COSM152022098 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 9
9 COSM143036610 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 9
10 COSM94289984 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 9
11 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 9
12 COSM96278984 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 9
13 COSM91370315 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1432+1G>C p.? 11:32391971-32391971 9
14 COSM91379363 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.536C>A p.P179H 11:32434810-32434810 9
15 COSM89581411 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 23:54238942-54238942 9
16 COSM101322652 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13:41865963-41865963 9
17 COSM101325565 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13:41701456-41701456 9
18 COSM96870566 VTCN1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.98-1G>T p.? 1:117156922-117156922 9
19 COSM94748869 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860= 8:99274262-99274262 9
20 COSM88289499 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>T p.V130F 3:10146561-10146561 9
21 COSM88290593 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.464-1G>A p.? 3:10149786-10149786 9
22 COSM88305492 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.291C>A p.P97= 3:10142138-10142138 9
23 COSM88291276 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.343C>T p.H115Y 3:10146516-10146516 9
24 COSM88303076 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.293A>T p.Y98F 3:10142140-10142140 9
25 COSM88289037 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.254T>C p.L85P 3:10142101-10142101 9
26 COSM88289748 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>G p.Y175* 3:10149848-10149848 9
27 COSM88292344 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 3:10142133-10142133 9
28 COSM88292485 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.241C>T p.P81S 3:10142088-10142088 9
29 COSM88307936 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.244C>T p.R82C 3:10142091-10142091 9
30 COSM88289384 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.263G>T p.W88L 3:10142110-10142110 9
31 COSM88290429 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.350G>T p.W117L 3:10146523-10146523 9
32 COSM88294468 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.473T>G p.L158R 3:10149796-10149796 9
33 COSM88292596 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.490C>T p.Q164* 3:10149813-10149813 9
34 COSM88292160 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.551T>C p.L184P 3:10149874-10149874 9
35 COSM88290922 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.345C>G p.H115Q 3:10146518-10146518 9
36 COSM88289274 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 3:10142041-10142041 9
37 COSM88292304 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.269A>T p.N90I 3:10142116-10142116 9
38 COSM88288882 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>A p.S68* 3:10142050-10142050 9
39 COSM88305342 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.492G>T p.Q164H 3:10149815-10149815 9
40 COSM88290983 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.506T>C p.L169P 3:10149829-10149829 9
41 COSM88289268 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 3:10142041-10142041 9
42 COSM88292994 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.533T>C p.L178P 3:10149856-10149856 9
43 COSM88297200 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.340G>C p.G114R 3:10142187-10142187 9
44 COSM88300743 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.278G>A p.G93D 3:10142125-10142125 9
45 COSM88292961 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.331A>C p.S111R 3:10142178-10142178 9
46 COSM88297366 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.565G>A p.E189K 3:10149888-10149888 9
47 COSM88289588 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.233A>T p.N78I 3:10142080-10142080 9
48 COSM88293594 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-1G>C p.? 3:10146513-10146513 9
49 COSM88289109 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.350G>A p.W117* 3:10146523-10146523 9
50 COSM88290637 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.464-1G>C p.? 3:10149786-10149786 9

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

GO Terms for Clear Cell Renal Cell Carcinoma

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....